Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$10.6 - $16.6 $1.48 Million - $2.32 Million
-139,979 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$10.3 - $17.3 $1.44 Million - $2.42 Million
139,979 New
139,979 $179,000
Q3 2019

Nov 14, 2019

SELL
$20.0 - $24.6 $2.12 Million - $2.61 Million
-106,026 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$18.6 - $28.2 $1.97 Million - $2.99 Million
106,026 New
106,026 $231,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $12.4M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Cvi Holdings, LLC Portfolio

Follow Cvi Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cvi Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cvi Holdings, LLC with notifications on news.